Welcome to our dedicated page for Enliven Therapeutics SEC filings (Ticker: ELVN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Enliven Therapeutics, Inc. (Nasdaq: ELVN) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a clinical-stage biopharmaceutical issuer. Enliven files a range of documents with the U.S. Securities and Exchange Commission (SEC), including annual reports on Form 10-K, quarterly reports on Form 10-Q, and current reports on Form 8-K describing material events.
For Enliven, Form 8-K filings are particularly relevant to investors monitoring clinical-stage and corporate milestones. Recent 8-Ks have covered topics such as quarterly financial results, leadership changes including the appointment of a new President and Chief Executive Officer, the adoption of the 2025 Inducement Equity Incentive Plan, and related compensatory arrangements. Amendments on Form 8-K/A may be used to correct or update previously furnished information, such as earnings press releases.
Periodic reports on Form 10-K and Form 10-Q (referenced in Enliven’s press releases) contain more detailed information on research and development expenses, general and administrative costs, net loss, cash, cash equivalents and marketable securities, as well as risk factors and management’s discussion and analysis. These filings help contextualize the company’s ability to fund the ENABLE Phase 1 trial of ELVN-001 and potential future studies.
On Stock Titan, users can review Enliven’s SEC filings alongside AI-powered summaries that explain key points in accessible language, highlight important sections, and help interpret complex disclosures. Real-time updates from EDGAR allow quick access to new filings, while specialized forms such as Form 4 (when available) can be used to track insider equity transactions. This page is a practical starting point for understanding Enliven’s regulatory history, financial reporting, equity plans and material corporate events related to its precision oncology programs.
Enliven Therapeutics insider Joseph Lyssikatos has filed a Form 144 notice to sell 75,000 common shares. The shares are to be sold through Jefferies LLC on Nasdaq, with an indicated aggregate market value of $1,743,750.00. The filing notes that there were 59,000,000 shares of this class outstanding.
The 75,000 shares were originally acquired as founder shares from Enliven Therapeutics on 09/01/2019. The form also lists recent sales by Lyssikatos over the past three months, including 12,500 shares on 10/20/2025, 12,500 on 11/19/2025, 5,000 on 12/19/2025, 41,302 on 01/08/2026, and 41,198 on 01/09/2026, each with disclosed gross proceeds. By signing, the seller represents they are not aware of any undisclosed material adverse information about the company.
Enliven Therapeutics insider plans to sell additional shares under Rule 144. A notice has been filed to sell 75,000 shares of Enliven Therapeutics common stock through Jefferies LLC on Nasdaq, with an aggregate market value of $1,743,750 and 59,000,000 shares outstanding. The shares to be sold are founder shares originally acquired on September 1, 2019 from Enliven Therapeutics.
The filing also lists prior sales over the past three months by the same seller, including 12,500 Enliven Therapeutics securities sold on November 17, 2025 for $272,739.30 and 38,757 sold on January 8, 2026 for $930,261.95, plus an additional 43,743 sold on January 9, 2026 for $1,089,200.70.
Enliven Therapeutics insider Anish Patel has filed a notice to sell common stock under Rule 144. The filing covers 48,300 common shares to be sold through Jefferies LLC on or about 01/09/2026 on the Nasdaq market, with an aggregate market value of $1,122,975.00. The filing notes 59,000,000 shares of the issuer’s stock outstanding.
The shares to be sold are founder shares of common stock acquired from Enliven Therapeutics on 09/01/2019. Over the past three months, Patel has already sold 6,667 shares for gross proceeds of $116,034.33 on 11/07/2025 and 6,663 shares for gross proceeds of $140,072.92 on 12/08/2025. By signing, the seller represents that he is not aware of any undisclosed material adverse information about the company’s current or prospective operations.
Enliven Therapeutics insider plans a new stock sale under Rule 144. A Form 144 notice discloses an intention to sell up to 82,500 shares of common stock through Jefferies LLC on Nasdaq, with an approximate sale date of 01/08/2026. The filing lists an aggregate market value of $1,276,275.00 for these shares, against 59,000,000 common shares outstanding.
The 82,500 shares are described as founder shares acquired from Enliven Therapeutics on 09/01/2019. Over the past three months, the same seller, Samuel Kintz, reported sales of Enliven Therapeutics stock: 12,500 shares on 10/17/2025 for $266,653.75, 12,500 shares on 11/17/2025 for $272,739.30, and 5,000 shares on 12/17/2025 for $81,892.60.
Enliven Therapeutics insider Joseph Lyssikatos has filed a Rule 144 notice to sell up to 82,500 shares of common stock through Jefferies LLC on Nasdaq, with an aggregate market value of $1,276,275.00. The filing notes that 59,000,000 shares of this class were outstanding and that the planned sale is expected around 01/08/2026.
The shares to be sold are described as founder shares acquired from Enliven Therapeutics on 09/01/2019. Over the prior three months, Lyssikatos sold additional Enliven Therapeutics Inc shares in three transactions: 12,500 shares on 10/20/2025 for $276,024.53, 12,500 shares on 11/19/2025 for $279,155.45, and 5,000 shares on 12/19/2025 for $84,206.00.
Enliven Therapeutics, Inc. (ELVN) has a Form 144 filing for a planned insider sale of common stock. The notice covers a proposed sale of 1,620 common shares through broker Jefferies LLC on the Nasdaq, with an aggregate market value of $25,061.40. The filing lists 59,000,000 shares of the same class outstanding, showing this planned sale is a very small portion of the total. The shares were originally acquired on 02/25/2020 in a previous purchase from Enliven Therapeutics, Inc. The signer of the notice represents that they are not aware of undisclosed material adverse information about the company.
Enliven Therapeutics received a Form 144 notice from a holder planning to sell 12,300 shares of its common stock. The planned sale, through Jefferies LLC, has an indicated aggregate market value of $190,281.00, with an approximate sale date of 01/08/2026 on the Nasdaq exchange. The filing notes that 59,000,000 shares of common stock are outstanding.
The 12,300 shares to be sold were acquired on 01/25/2020 as founders shares from Enliven Therapeutics, with the same date shown as the date of payment and the nature of payment listed as “N/A.” The notice also includes the standard representation that the seller does not know of any undisclosed material adverse information about the issuer.
Enliven Therapeutics reported changes to its board of directors. On January 6, 2026, the board appointed Scott Garland as a Class I director, with his term running until the 2027 annual meeting of stockholders, and named him Chair of the Nominating and Corporate Governance Committee effective January 7, 2026.
Garland previously consulted for the company from January 2024 until his appointment, receiving $314,650 and vesting in stock options to purchase 26,580 shares of common stock. As an outside director, he will receive annual cash compensation of $40,000 for board service and $10,000 for chairing the nominating committee, plus new stock options with a grant date fair value of about $650,000 that vest monthly over three years and fully vest upon a Change in Control. The company also entered into its standard indemnification agreement with him.
On the same day, Andrew Phillips, Ph.D. informed the board that he is resigning from the board, the Audit Committee, and the Nominating Committee effective January 7, 2026. His resignation is stated not to result from any disagreement regarding the company’s operations, policies, or practices.
Enliven Therapeutics, Inc. filed a registration statement to register 875,000 shares of its Common Stock reserved for issuance under the company’s 2025 Inducement Equity Incentive Plan. This plan is intended to grant equity awards to eligible individuals as an inducement to join or remain with the company. The filing also incorporates by reference Enliven’s previously filed annual, quarterly, and current reports, and describes standard Delaware law and company provisions for indemnifying directors and officers, including related insurance and indemnification agreements.
Enliven Therapeutics, Inc. reported that an individual serving as its President, CEO and Director has no beneficial ownership of the company’s securities as of 12/11/2025. Filed pursuant to Section 16(a) of the Exchange Act, the report indicates that this person does not hold any non-derivative or derivative securities of Enliven Therapeutics despite their leadership and board roles.